This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: heart failure

September 2010 Br J Cardiol 2010;17:209

Latest NICE guidance on chronic heart failure

BJ Cardio Staff

Abstract

The new guideline, which covers the management of heart failure in adults in primary and secondary care, contains new and updated recommendations on diagnosis, pharmacological treatment, monitoring and rehabilitation. Key priorities for implementation in the guidance include: Referring patients with suspected heart failure and previous myocardial infarction (MI) to transthoracic Doppler 2D echocardiography and specialist assessment within two weeks. Measuring serum natriuretic peptides in patients with suspected heart failure without previous MI; referring those with very high levels of serum natriuretic peptides to urgent transthoracic Dopp

| Full text
News from the 2010 Congress of the European Society of Cardiology

September 2010 Br J Cardiol 2010;17:211-14

News from the 2010 Congress of the European Society of Cardiology

Abstract

Highlights of this year’s European Society of Cardiology Congress, held in Stockholm, Sweden, from August 28th to September 1st included a new drug which benefits heart failure by slowing heart rate, and more exciting results from oral compounds that could replace warfarin in various indications. Highlights of this year’s European Society of Cardiology Congress, held in Stockholm, Sweden, from August 28th to September 1st included a new drug which benefits heart failure by slowing heart rate, and more exciting results from oral compounds that could replace warfarin in various indications. SHIFT: ivabradine shows benefit in heart failure

| Full text

September 2010 Br J Cardiol 2010;17:209

In Brief

BJ Cardio Staff

Abstract

New NT-proBNP test Roche Diagnostics has announced the launch of a new NT-proBNP+ test, which it says can give a result in under 15 minutes when tested on its cobas h232 near-patient testing meter. In addition, the test has an extended measuring range (60 – 9000pg/ml). The test can serve as an aid in the diagnosis of suspected heart failure, in the monitoring of compensated left ventricular dysfunction and in the risk stratification of patients with acute coronary symptoms. Recent recommendations of a consensus group (Br J Cardiol 2010;17:76-80) highlight the importance of B-type natriuretic peptide (NP) testing for heart failure. NP testi

| Full text

July 2010 Br J Cardiol 2010;17:163-5

Eplerenone beneficial in mild heart failure 

BJ Cardio Staff

Abstract

According to Pfizer, an interim analysis of the trial showed that patients treated with eplerenone in addition to current standard of care experienced a significant reduction in risk of cardiovascular death or heart failure hospitalisation compared with those in the placebo arm of the trial.  The company says it is now working to ensure that all patients are informed of this decision, and an amendment to the protocol will be requested to allow all consenting patients to start treatment with eplerenone in an open-label extension of the study, after completing a close-out visit ending the double-blind, placebo-controlled phase.  Eplerenone is

| Full text

May 2010 Br J Cardiol 2010;17:s10-s12

ARBs in chronic heart failure

Theresa McDonagh

Abstract

Current treatments The National Institute for Health and Clinical Excellence (NICE) published guidelines on the diagnosis and management of chronic heart failure in 2003,5 with more recent guidelines being published by the European Society of Cardiology (ESC)6 in 2008. The treatment algorithm recommended for patients with heart failure due to left ventricular systolic dysfunction in the ESC guideline is shown in figure 1. Figure 1. Treatment strategy for use of drugs and devices in patients with symptomatic heart failure and systolic dysfunction Based on these guidelines, current first-line pharmacological therapy comprises a combination of o

| Full text
In brief

May 2010 Br J Cardiol 2010;17:117

In brief

BJ Cardio Staff

Abstract

New pocket-sized visualisation tool This new pocket-sized visualisation tool provides ultrasound technology at the point-of-care. Similar in size to a mobile phone and weighing less than one pound, it can give high quality colour images enabling physicians to take a quick look inside the body and detect disease earlier. Vscan™ is marketed by GE Healthcare and has received the CE Mark by the European Union. Heart failure report published A comprehensive review of the quality of heart failure care in England Bridging the quality gap: heart failure, has been published by The Health Foundation. It highlights that prevention is key to imp

| Full text

March 2010 Br J Cardiol 2010;17:67-8

Cardiorenal syndrome: one disease – two paths?

Abstract

Introduction That renal and cardiac disease appear inseparable from an epidemiological perspective is unsurprising, since they share many risk factors, notably hypertension, diabetes and inflammation. To date, however, our focus on the disparate specialities of ‘cardiology’ and ‘nephrology’ has reinforced a perception of each system as separate. The Cardiorenal Forum (CRF) was established to challenge this perspective. The most recent meeting, last autumn, ‘Optimising care at the cardiorenal interface’ was organised by the Royal College of Physicians, the British Cardiovascular Society and the Renal Association, in association wit

| Full text

March 2010 Br J Cardiol 2010;17:73–5

State financial assistance for terminally ill patients: the discrepancy between cancer and heart failure

Rumina Önaç, Nigel C Fraser, Miriam J Johnson

Abstract

We reviewed the use of DS1500 applications for state financial benefits for patients dying from cancer (n=54) and heart failure (n=24) in one primary care practice. There was a marked inequality in favour of those with cancer, both in terms of DS1500 application form usage (cancer 33% versus heart failure 0%), but also access to palliative care service referrals (cancer 54% versus heart failure 8%) and discussion in Gold Standards Framework practice meetings (cancer 61% versus heart failure 4%). There should be equal provision of a ‘gold standard’ of care for patients with terminal disease irrespective of aetiology. Background High-qualit

| Full text
Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland

March 2010 Br J Cardiol 2010;17:76–80

Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland

Martin R Cowie, Paul O Collinson, Henry Dargie, FD Richard Hobbs, Theresa A McDonagh, Kenneth McDonald, Nigel Rowell

Abstract

There is firm evidence for NP testing as part of the heart failure diagnostic pathway. Measuring NPs is also a useful prognostic tool and can help with discharge planning, and there is emerging evidence for use in treatment monitoring particularly in younger patients. For the future, NP measurement might also prove to be useful for screening high-risk patients for asymptomatic left ventricular systolic dysfunction. Introduction The prognosis for patients with heart failure is considerably better than it was 10 years ago, but certain aspects of care need to be improved. A Healthcare Commission audit in 2007 reported that the delivery of heart

| Full text

February 2010 Br J Cardiol 2010;17:21

In brief

BJCardio editorial staff

Abstract

Coffee consumption shows CHD benefits in women A meta-analysis of a number of cohorts studies published in the International Journal of Cardiology (2009;137:216-25) demonstrates that habitual coffee consumption may be associated with a lower risk of coronary heart disease (CHD) in women. Analysis of data from 21 cohort studies showed that moderate coffee consumption (of up to four cups of coffee per day) were associated with a 18% reduction in risk of CHD in women.  The investigators note that such an effect was unlikely to be caused by chance. Further benefits have been shown from a meta-analysis published in the Archives of Internal Medici

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now